{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:43Z","timestamp":1791908143220,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.017","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T19:42:36Z","timestamp":1672083756000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5488","authenticated-orcid":false,"given":"Christian D.","family":"Fankhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-6052","authenticated-orcid":false,"given":"Matthew G.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nossiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sujenthiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2335","authenticated-orcid":false,"given":"Jan","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.12.017_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low\u2013prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2022.12.017_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cncr.29691","article-title":"Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer","volume":"122","author":"Mahal","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.12.017_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.05.035","article-title":"Inferior cancer survival for men with localized high-grade prostate cancer but low prostate-specific antigen","author":"Fankhauser","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2022.12.017_bib4","article-title":"Association of very low PSA with increased metastases and death in patients with biopsy Gleason score 8-10 prostate cancer","volume":"19","author":"Pompe","year":"2020","journal-title":"Euro Urol Open Sci"},{"key":"10.1016\/j.ejca.2022.12.017_bib5","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/j.1464-410X.2011.10628.x","article-title":"Outcomes in patients with Gleason score 8\u201310 prostate cancer: relation to preoperative PSA level","volume":"109","author":"McGuire","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2022.12.017_bib6","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijrobp.2010.12.064","article-title":"Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8\u201310 prostate cancer treated with primary radiotherapy","volume":"81","author":"Krauss","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.12.017_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-0045(20010201)46:2<126::AID-PROS1016>3.0.CO;2-7","article-title":"Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer","volume":"46","author":"Lilleby","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2022.12.017_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/pros.22771","article-title":"Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7\u201310 prostate cancer treated with definitive radiotherapy","volume":"74","author":"Krauss","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2022.12.017_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clon.2013.10.006","article-title":"The National Prostate Cancer Audit-introducing a new generation of cancer audit","volume":"26","author":"Aggarwal","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.017_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: national cancer registration dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2022.12.017_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/0310057X0603400316","article-title":"Data linkage enables evaluation of long-term survival after intensive care","volume":"34","author":"Williams","year":"2006","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.ejca.2022.12.017_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/bjs.6930","article-title":"Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score","volume":"97","author":"Armitage","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2022.12.017_bib13","first-page":"5304","article-title":"Testosterone replacement therapy and risk of favorable and aggressive prostate cancer","volume":"69","author":"Loeb","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.017_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2022.12.017_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Control"},{"key":"10.1016\/j.ejca.2022.12.017_bib16","series-title":"Regression modeling strategies","author":"Harrell","year":"2001"},{"key":"10.1016\/j.ejca.2022.12.017_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2022.12.017_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euf.2018.08.024","article-title":"The U shape of prostate-specific antigen and prostate cancer-specific mortality in high-grade metastatic prostate adenocarcinoma","volume":"6","author":"Wang","year":"2020","journal-title":"Euro Urol Focus"},{"key":"10.1016\/j.ejca.2022.12.017_bib19","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.21.00596","article-title":"Radiation and androgen deprivation therapy with or without docetaxel in the management of nonmetastatic unfavorable-risk prostate cancer: a prospective randomized trial","volume":"39","author":"D'Amico","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.017_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.12.017_bib21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM198511143132005","article-title":"The autopsy as a measure of accuracy of the death certificate","volume":"313","author":"Kircher","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.12.017_bib22","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.ijrobp.2022.07.459","article-title":"Sequencing of androgen deprivation therapy of short duration with radiotherapy for non-metastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"114","author":"Ma","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.12.017_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.12.017_bib24","series-title":"National prostate cancer Audit short report for September","year":"2022"},{"key":"10.1016\/j.ejca.2022.12.017_bib25","article-title":"Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study","author":"Parry","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2022.12.017_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/pubmed\/fdr054","article-title":"Systematic review of discharge coding accuracy","volume":"34","author":"Burns","year":"2012","journal-title":"J Public Health"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:06Z","timestamp":1760733606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922018287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":26,"alternative-id":["S0959804922018287"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}